National Quality Indicator – Prescribing Continuous Prophylaxis

Increase the proportion of severe hemophilia A patients over the age of two years for whom continuous prophylaxis was prescribed in the past year by age category.

Data Source: ATHNdataset
2014 Baseline: 2015 Result: 2016 Most Recent Result:
3-12 years: 72.8%
13-18 years: 77.6%
19-29 years: 64.6%
30-49 years: 45.4%
50-74 years: 33.21
3-12 years: 77.9%
13-18 years: 82.1%
19-29 years: 69.0%
30-49 years: 51.7%
50-74 years: 39.2%
3-12 years: 81.93%
13-18 years: 88.33%
19-29 years: 76.99%
30-49 years: 59.94%
50-74 years: 47.43%
Total: 2,189 Total: 2,533 Total: 2,945

Calculation:
Numerator: Number of active patients with severe hemophilia A without an inhibitor who were prescribed continuous prophylaxis during the past calendar year by age category.
Denominator:  Number of active patients with severe hemophilia A without an inhibitor by age category. 

2015 Conclusion: The proportion of patients with severe hemophilia A without an inhibitor over the age of 2 years who were prescribed continuous prophylaxis during the past calendar year ranged from 39.16% for patients ages 50-74 and peaked at 82.14% for ages 13-18 years. Slight increases were seen across all ages between 3 and 74 years.

2016 Conclusion: The proportion of patients with severe hemophilia A without an inhibitor over the age of 2 years who were prescribed continuous prophylaxis during the past calendar year ranged from 47.43% for patients ages 50-74 and peaked at 88.33% for ages 13-18 years. Slight increases were seen across all ages between 3 and 74 years.